Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are rare X-linked recessive ailments impacting 1 in 7,250 people in the United States (U.S.). Currently, DMD has no known cure. Disease management is aimed at preserving the quality of life and extending survival. The objective of this study is to assess economic burden, current economic evaluation techniques, and data sources for DMD economic evaluation and identify evidence gaps in DMD burden and provide details on the value of existing DMD treatments.
Contact us at insights@axtria.com with any questions.